LYNPARZA AstraZeneca Pty Ltd
Product name
LYNPARZA
Sponsor
Accepted date
Jan-2024
Active ingredients
olaparib
Proposed indication
Indicated for the maintenance treatment of advanced or recurrent endometrial cancer.
Application type
C (new indication)
Publication date
Jan-2024